

YOUR PARTNER IN SUBSIDIES & FUNDING

we raised >200 million euro in funding
for research & development projects



Catalyze[®]
CARRYING IDEAS FORWARD

Why Catalyze?



Catalyze is a full service consultancy firm specialized in the life science, biotechnology and medical technology. Our main focus is to raise national and international grants for innovative companies, research institutes, academic hospitals and universities. In addition to grants, Catalyze has a strong track record in obtaining support through fiscal stimulus programs, government secured loans and investments/venture capital. Our company also provides professional services in project management and administration of awarded projects. Moreover, we provide the essential support to life science companies and researchers in commercializing their research and innovations.

Our dedicated consultants all have a relevant background in the life science (PhD, MD) with the highest success rate in obtaining funding for your pre-clinical, translational and clinical research and development projects. Catalyze provide experts and a vast network of partners in relevant fields like business planning, business support, legal and regulatory aspects, IP management and licensing, as well as experts in clinical trials, trial design and monitoring.



COMPLETE FUNDING SOLUTIONS

We apply our creativity and industry knowledge to every project on a bespoke basis, developing a financial plan for your research and development projects using subsidies, government secured loans and tax programs that minimize costs, risk and time frames (not to mention frustration). This will not only provide non-dilutive financing but provides a total financial solution to fund your research ideas and product development programs.



UNBURDENING

We plan, we create, and we manage. Our comprehensive service is designed to make your life easier. After an initial meeting, we identify the financing possibilities most relevant to your specific project. We subsequently take the full funding application process out of your hands and manage the work involved in writing and submitting applications.



CONSORTIUM BUILDING

The development of partnerships and consortia is a vital element of successful and modern business and is becoming more and more important, especially in multi-disciplinary and international projects in the life sciences. Catalyze has a network of over 400 companies and research institutes within and outside Europe, offering great opportunities for partner search and consortium building. This will enable you to be part of a strong research and development effort, increasing the chances of success and getting your grant funded.



AFTER CARE

Project coordination, management and administration are key to run a successful project with well-defined aims, timeframes and financial input. Catalyze can support your project also after funding has been awarded, so you and your partners can focus on the actual research and development.

Our clients

Our clients include a broad range of companies and organizations in the field of life sciences & health: biotechnology and pharmaceutical companies, universities, research institutes and medical centers, public-private partnerships, and educational institutions.

Our track record

Catalyze has an unparalleled track record and success rate (70%), after submitting many large (international) proposals with high complexity, together with research groups and life sciences companies in more than 20 countries. Over the past decade, we have raised more than 200 million euro in funding for research and development projects.

How do we work

Practical examples



Project title:

TISSUE ENGINEERED SKIN WITH HUMAN HAIR FOLLICLES FOR HUMAN TRANSPLANTATION AND *IN VITRO* SKIN TESTING

Grant:

EUROSTARS

The Eurostars program supports European research-performing small to medium sized enterprises, which develop innovative products, processes and services, to gain competitive advantage. To this end, Eurostars funds transnational collaborative innovation projects resulting in products that can be rapidly commercialized.



THE IDEA

Prof. dr. Sue Gibbs is an expert in skin tissue engineering and co-founder of A-Skin BV, a spin-off company of the VU university medical center (VUmc) that develops and commercializes novel techniques for the treatment of difficult-to-heal skin wounds. The research team at the VUmc recently developed an autologous skin equivalent for acute wounds (e.g. burns): Acutis®. The next step will be to include functioning hair follicles to improve the esthetic outcome of scalp wound treatment.



WHAT WE DID

Catalyze formed an academic-industry consortium consisting of four partners, including A-Skin and the VUmc. Together with this consortium, Catalyze set up a project to achieve the bio-engineering of hair follicles in *in vitro* cultured skin and the development of two main applications: 1) a skin construct for hair regeneration, and 2) an *in vitro* skin model including hair follicles for substance testing and drug screening.

Catalyze carried out the complete application (proposal writing, and coordinating the discussion on activities, budgets, co-funding and collaborative agreements) and its submission to the Eurostars office in Brussels, and provided guidance for national applications after favorable international ranking of the project.



THE RESULT

This project was one of the projects selected and awarded from 299 submitted proposals. It has a total budget of €1.8 million and is supported with €1M by the Eurostars program. The project started beginning 2015, and in 2019 both the clinical application of the skin equivalent including hair follicles and the commercial application (contract research service) of the *in vitro* skin model are anticipated.

How do we work

Practical examples

2



Project title:

REACTION!

Grant:

HORIZON 2020 ON EBOLA RESEARCH

In response to the deadly and destructive Ebola outbreak in West Africa in 2014, the European Commission opened a call aimed at urgently needed Ebola research. The goal of this call was to address both the emergency situation and at the same time have a long-term response to Ebola virus disease.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no.666092



THE IDEA

In response to the Horizon 2020 call opening, an international team of Ebola experts, led by INSERM (Institut National de la Santé et de la Recherche Médicale) in France, initiated the REACTION! project to study the safety and efficacy of Favipiravir, an antiviral drug already licensed for influenza. Previous *in vitro* and *in vivo* studies identified Favipiravir as a promising candidate to treat Ebola, however, the drug was never tested on human Ebola patients. The idea of the REACTION! project was to evaluate the performance of Favipiravir in a fast-track study to address the safety and efficacy of the drug in an animal model of the disease, as well as in patients with Ebola virus disease. In addition, this project would allow the experts to address the social challenges with respect to the Ebola outbreak in West Africa, including social mobilization and community engagement



WHAT WE DID

In order to start working as soon as possible, the Horizon 2020 Ebola Research call asked EU researchers to submit a full Horizon 2020 project proposal within 2½ weeks via a fast-track procedure. Catalyze took control of all aspects of the REACTION! project proposal, allowing the project partners to meet this tight and challenging deadline. This included organizing telephone conferences with all international partners to guide the decision-making process with respect to the work plan, writing the project proposal, fine-tuning the project details and connecting the separate fields of expertise in the project. In addition, Catalyze drafted the budget for the twelve participating partners and made sure letters of support from important organizations (such as the Guinea government and the International Red Cross) were submitted together with the project proposal.



THE RESULT


REACTION! was one of the five projects selected to receive funding for Ebola research via a fast-track procedure, and was awarded with a > € 2.5M grant by the European Commission at the end of October 2014. Within days after the funding results came in, the researchers started their work and project partners travelled to Guinea to prepare the work as described in the REACTION! project proposal. While the consortium partners are focusing on their research, Catalyze is responsible for the project management of this ambitious 2-year project.

OUR OFFER

With a range of value-adding activities, Catalyze can help your research and development projects grow and develop. Contact us to learn how we can launch your business on the path to success. We can provide you with a complete quote of all costs involved or work with a fee structure.

FOR MORE INFORMATION

Do you see opportunities for a subsidy tender, or would you like to discuss further possibilities? Please don't hesitate to contact the Catalyze consultants!



Catalyze[®]
CARRYING IDEAS FORWARD

Catalyze B.V.
Joop Geesinkweg 167
1114 AB Amsterdam-Duivendrecht
The Netherlands

info@catalyze.nl
T: +31 (0)20 – 723 4400